Clinuvel Pharmaceuticals Ltd

BRIEF

published on 03/26/2026 at 12:50, 3 hours ago

CLINUVEL Pharmaceuticals: A Promising Investment with New Developments

SCENESSE NASDAQ Uplisting CLINUVEL Pharmaceuticals NEURACTHEL Erythropoietic Protoporphyria
PRESS RELEASE

published on 03/26/2026 at 12:45, 3 hours 5 minutes ago

Original-Research: CLINUVEL Pharmaceuticals Limited (von Parmantier & Cie. GmbH): Buy
Update on CLINUVEL Pharmaceuticals Limited research by Parmantier & Cie. GmbH. Analysts expect significant revenue growth with new product NEURACTHEL®. Positive news flow anticipated in markets and development activities

Revenue Growth Investment Research NEURACTHEL CLINUVEL Pharmaceuticals Limited
BRIEF

published on 09/30/2025 at 10:57, 5 months 26 days ago

CLINUVEL Pharmaceuticals Strengthens Position with Strategic Moves

Capital Markets Biotech Growth NASDAQ Uplisting CLINUVEL Pharmaceuticals Trade Tariffs
PRESS RELEASE

published on 09/30/2025 at 10:52, 5 months 26 days ago

Original-Research: CLINUVEL Pharmaceuticals Limited (von Parmantier & Cie. GmbH): Buy
CLINUVEL strengthens global position with tariff advantage and Nasdaq uplisting. Strategic decisions by CLINUVEL highlighted in research note by Parmantier & Cie. GmbH

Global Growth Strategy Parmantier & Cie. GmbH NASDAQ Uplisting CLINUVEL Pharmaceuticals Tariff Advantage
BRIEF

published on 06/23/2025 at 12:46, 9 months 3 days ago

CLINUVEL Pharmaceuticals: Positive Outlook Amid Strategic Developments

Investment Recommendation North America Expansion SCENESSE® CLINUVEL Pharmaceuticals Vitiligo Treatment
PRESS RELEASE

published on 06/23/2025 at 12:41, 9 months 3 days ago

Original-Research: CLINUVEL Pharmaceuticals (von Parmantier & Cie. GmbH): Buy
Research update by Parmantier & Cie. GmbH on CLINUVEL Pharmaceuticals, highlighting CEO's return and business model enhancement with SCENESSE® for vitiligo in North America. Strategic growth opportunities discussed

Research Update Strategic Growth CLINUVEL Pharmaceuticals CEO Return SCENESSE For Vitiligo
BRIEF

published on 03/07/2025 at 16:26, 1 year ago

CLINUVEL Pharmaceuticals Sees Record Growth in H1/FY25

Investment Strategy Market Expansion Record Growth CLINUVEL Pharmaceuticals Clinical Projects
PRESS RELEASE

published on 03/07/2025 at 16:21, 1 year ago

Original-Research: CLINUVEL Pharmaceuticals (von Parmantier & Cie. GmbH): BUY
CLINUVEL Pharmaceuticals demonstrates impressive H1/FY25 results, increasing revenue and EPS. New strategy focuses on vitiligo treatment, leading in science-based cosmetic products

Investment Recommendation CLINUVEL Pharmaceuticals H1/FY25 Results Vitiligo Treatment Cosmetic Products

Published on 03/26/2026 at 14:05, 1 hour 46 minutes ago

SouthGobi Announces Profit Warning
Published on 03/26/2026 at 13:00, 2 hours 51 minutes ago

Prospect Ridge Strengthens Technical Team with Appointment of Phil Smerchanski as Senior Technical Advisor
Published on 03/26/2026 at 13:00, 2 hours 51 minutes ago

GameSquare's Stream Hatchet Launches Creator Communities to Manage the Full Creator Marketing Lifecycle
Published on 03/26/2026 at 12:59, 2 hours 52 minutes ago

Adcore Concludes Fiscal Year 2025 With Strong Q4 Performance
Published on 03/26/2026 at 12:45, 3 hours 6 minutes ago

Quartz Mountain Reports Strong Warrant Exercise Participation and Provides Exploration Update at Maestro Project, Central British Columbia

View all ACCESSWIRE

Published on 03/26/2026 at 15:25, 25 minutes ago

Duck Creek Loss Control Named 2026 Insurance Luminary Finalist by PropertyCasualty360
Published on 03/26/2026 at 15:23, 27 minutes ago

Sartorius AG - Resolutions of the Annual General Meeting
Published on 03/26/2026 at 15:05, 45 minutes ago

JOY GROUP Announces 2025 Financial Results, Revenue Surpasses US$620M
Published on 03/26/2026 at 15:01, 49 minutes ago

EQS-Adhoc: CENIT AG decides to switch from the Regulated Market (Prime Standard) to the Scale Segment of the Frankfurt Stock Exchange
Published on 03/26/2026 at 15:00, 51 minutes ago

OLB’s financial performance remains at a consistently high level

View all EQS

Published on 03/26/2026 at 08:57, 6 hours 53 minutes ago

Edenred statement
Published on 03/26/2026 at 07:30, 8 hours 21 minutes ago

BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY
Published on 03/25/2026 at 18:53, 20 hours 57 minutes ago

LNA SANTE : 2025 Annual Results
Published on 03/25/2026 at 18:31, 21 hours 20 minutes ago

Strong investment performance and active roll-out of our strategy
Published on 03/25/2026 at 17:45, 22 hours 6 minutes ago

Combined General Meeting on May 05, 2026: publication of the notice of Meeting

View all LES ECHOS COMFI WIRE

News